Verification of physostigmine sulfate particle-size distribution prior to low-dose tablet compression is conducted by laser diffraction per USP <429>, with a target volume median diameter Dv50 of 20–50 µm and a Dv90 not exceeding 150 µm for direct-compression blends. The API powder is first passed through a 500 µm stainless-steel sieve to deagglomerate and then blended with lactose monohydrate NF and microcrystalline cellulose PH-101 in a V-blender at 25 rpm for 20 minutes. Lubrication with magnesium stearate 0.5% w/w is performed as a final blending step for 3 minutes to minimize overlubrication-induced reduction in tablet tensile strength. Content uniformity in tablets at 0.1 mg and 0.25 mg strengths is verified by HPLC-UV at 254 nm per USP <905> Uniformity of Dosage Units, with acceptance value ≤ 15.0 and individual assay values between 85.0% and 115.0% of label claim. Dissolution testing in 900 mL of 0.1 N hydrochloric acid at 37°C ± 0.5°C using USP <711> Apparatus 2 at 50 rpm must demonstrate not less than 75% of the labeled amount dissolved within 45 minutes. Finished tablets are round, flat-faced, scored, debossed with a batch-specific identifier, and packaged in amber glass bottles with 1 g silica gel desiccant canisters to limit moisture uptake. Regulatory oversight for these compounded preparations falls under USP <795> Pharmaceutical Compounding—Nonsterile Preparations and FDA 21 CFR Part 210/211 where applicable to pharmacy-based repackaging. Because physostigmine sulfate is hygroscopic and thermally labile, tableting suites are maintained at 18°C–22°C with relative humidity below 40% RH.

What Limits Physostigmine Salicylate Injection to Aseptic Filtration Rather Than Terminal Autoclaving?

Aseptic filtration rather than terminal autoclaving is mandated for physostigmine salicylate injection USP 1 mg/mL because the carbamate ester linkage undergoes thermal hydrolysis with first-order kinetics above 100°C, generating eseroline and methylcarbamic acid as principal degradants that elute as late-eluting peaks in HPLC-UV analysis at 246 nm. The aqueous vehicle is prepared in Water for Injection that is nitrogen-sparged for not less than 15 minutes to reduce dissolved oxygen below 0.5 ppm, then adjusted to pH 4.0–5.0 with hydrochloric acid to maintain the API in its protonated, hydrolysis-resistant form. Sodium metabisulfite 0.1% w/v is incorporated as an antioxidant, and the solution is filtered through a 0.22 µm polyethersulfone capsule filter at a flow rate not exceeding 500 mL/min per 10-inch cartridge to preserve membrane integrity under differential pressure below 15 psi. Filling proceeds in Class 5 isolators equipped with peristaltic pumps calibrated to deliver 1.10 mL ± 0.05 mL into 2 mL type I borosilicate glass ampoules under nitrogen overlay. The ampoules are sealed by flame fusion and subjected to 100% online leak testing by high-voltage spark detection, with acceptance threshold set at no visible electrical discharge through ampoule walls. Autoclave-based terminal sterilization at 121°C for 15 minutes has been reported in stability studies to produce drug-related impurity levels exceeding 5.0% total impurities within a single cycle, confirming that moist-heat sterilization is incompatible with this molecule. Sterility release testing follows USP <71> membrane filtration with fluid thioglycollate medium and soybean-casein digest medium incubated at 30–35°C and 20–25°C respectively for 14 days. Bacterial endotoxin limit per USP <85> is not more than 0.5 EU/mg of physostigmine salicylate. Injectable physostigmine salicylate is indicated in veterinary emergency medicine for reversal of anticholinergic toxidrome secondary to atropine, scopolamine, or tricyclic antidepressant overdose in dogs and cats, with intravenous doses of 0.02–0.04 mg/kg in dogs and 0.01–0.02 mg/kg in cats administered slowly over 1–2 minutes under continuous electrocardiographic monitoring. The finished dosage form is a sterile, clear, colorless to pale-yellow solution supplied in 1 mL or 2 mL single-dose ampoules, labeled with storage instructions to protect from light and refrigeration at 2°C–8°C.

Comparative Salt-Form Monograph Data for Veterinary API Sourcing

Parameter	Physostigmine Sulfate USP	Physostigmine Salicylate USP
Molecular weight (g/mol)	648.77	413.47
Aqueous solubility at 25°C	Freely soluble (1 g in 1–10 mL water)	Soluble (1 g in 30–100 mL water)
Melting range (°C)	140–142	184–186
Primary dosage form suitability	Ophthalmic solutions, oral tablets, powder compounding	Injectable solutions, lyophilized powders
Compendial monograph	USP Physostigmine Sulfate	USP Physostigmine Salicylate; EP 1612
Typical assay range (% w/w, dried basis)	98.0–102.0	98.5–101.5

In geriatric veterinary neurology referral practices, oral physostigmine sulfate tablets at 0.1 mg and 0.25 mg strengths are compounded extemporaneously for adjunctive management of canine cognitive dysfunction syndrome when standard therapy with selegiline is insufficient. The production environment for these nonsterile preparations is maintained at 18°C–22°C with relative humidity not exceeding 40% RH to prevent moisture uptake by the hygroscopic sulfate salt. Geometric dilution in a porcelain mortar is employed for the first trituration step: one part physostigmine sulfate is levigated with three parts lactose monohydrate NF until visually homogeneous by absence of white streaks under 3× magnification. The resulting triturate is transferred to a twin-shell V-blender operating at 25 rpm for 20 minutes with an intensifier bar speed of 1,440 rpm for the first 5 minutes of mixing to disperse agglomerates. Tablets are compressed on a rotary press fitted with 6.0 mm round flat-faced tooling, with compression force maintained between 8 kN and 12 kN to achieve tablet hardness of 5–7 kp measured on a Schleuniger hardness tester. Excipient formulation consists of lactose monohydrate NF 68.0% w/w, microcrystalline cellulose PH-101 30.0% w/w, croscarmellose sodium 1.5% w/w as disintegrant, and magnesium stearate 0.5% w/w as lubricant. Content uniformity per USP <905> requires acceptance value less than or equal to 15.0 across 10 dosage units, with HPLC-UV assay at 254 nm using a C18 column (150 mm × 4.6 mm, 5 µm) and a mobile phase of acetonitrile:phosphate buffer pH 3.0 (20:80 v/v). The terminal finished product is a round, film-coated tablet in amber glass bottles of 30 or 100 counts with child-resistant closures, labeled for storage at 2°C–8°C and protection from light. Published data for oral canine cognitive dysfunction therapy with physostigmine is limited to case series; no multi-center randomized controlled trial has been published in the American Journal of Veterinary Research or the Journal of the American Animal Hospital Association as of the 2025 literature review cutoff.

Particle Size Distribution Controls Content Uniformity in Low-Dose Physostigmine Tablet Cores

Content uniformity in low-dose physostigmine sulfate tablets is governed primarily by the particle size distribution of the API, because electrostatic charging and agglomeration propensity of the raw sulfate powder create segregation risk during direct-compression blending when the Dv90 exceeds 150 µm. Jet-milled physostigmine sulfate with a Dv50 of 20–30 µm and Dv90 of 75–100 µm, as measured by laser diffraction on a Malvern Mastersizer 3000 with dry dispersion at 2 bar, exhibits acceptable flowability with Carr's Index reduced to 18–22% compared with 30–35% for unmilled powder. The micronized material is incorporated into the blend using a staged addition sequence: first blended with an equal mass of lactose monohydrate NF for 10 minutes in a bin blender operating at 12 rpm, then this pre-blend is added to the remaining diluent and blended for an additional 15 minutes at 12 rpm. Blend uniformity testing is performed by sampling 10 locations with a thief sampler; relative standard deviation for physostigmine content must not exceed 5.0% across all sampling points. Compression is executed on a 16-station rotary tablet press at 35 rpm turret speed and 10 kN mean compression force, with die fill depth adjusted to maintain tablet weight of 100 mg ± 5 mg for the 0.25 mg strength and 120 mg ± 5 mg for the 0.1 mg strength. Process capability indices Cpk of less than 1.33 have been observed when relative humidity exceeds 45% RH during compression, attributable to powder adhesion to punch faces causing weight variation drift. The finished tablet cores are coated with a clear Opadry film coating to a 3.5% w/w weight gain in a perforated pan coater at 35°C inlet air temperature and 12 rpm pan speed. Terminal finished product is a film-coated, biconvex tablet meeting USP <905> and USP <711> dissolution specification of not less than 75% released in 45 minutes in 0.1 N HCl at 50 rpm paddle speed.

Compendial Compliance Matrix for Physostigmine Veterinary API Release

Test Parameter	Method / Instrument	Acceptance Limit	Standard Reference
Assay (sulfate/salicylate)	HPLC-UV at 254 nm / 246 nm	98.0–102.0% / 98.5–101.5% (dried basis)	USP 621; EP 1612
Optical rotation	Polarimeter, 589 nm, 20°C	Specific rotation range per monograph	USP 781
Loss on drying	Halogen moisture analyzer, 105°C	NMT 1.0%	USP 731
Residue on ignition	Muffle furnace, 600°C ± 50°C	NMT 0.1%	USP 281
Heavy metals	ICP-MS	Per ICH Q3D limits	ICH Q3D(R2)
Bacterial endotoxins (injectable grade)	LAL kinetic chromogenic	NMT 0.5 EU/mg	USP 85
Related substances (eseroline, rubreserine)	HPLC-UV gradient	Total impurities NMT 2.0%; individual NMT 0.5%	USP 621; EP 1612
Residual solvents	Headspace GC-FID	Class 3 solvents per ICH Q3C	ICH Q3C(R8)

When Physostigmine Sulfate Powder Is Dispersed into Non-Sterile Compounding Vehicles

Non-sterile compounding of physostigmine sulfate powder into veterinary oral suspensions or capsule formulations is performed in accordance with USP <795> and begins with verification of API identity by Fourier-transform infrared spectroscopy against an authenticated reference standard, followed by moisture content determination with a coulometric Karl Fischer titrator showing water content not exceeding 1.0%. The powder is levigated with a small volume of glycerin to form a smooth paste, then gradually incorporated into a vehicle of Ora-Plus and Ora-Sweet in a 1:1 ratio or into a methylcellulose 1% w/w gel for nasogastric administration. API concentration in compounded suspensions is typically 0.2 mg/mL to 1.0 mg/mL, with 0.1% w/w sodium benzoate added as preservative and the final pH adjusted to 5.0 with citric acid monohydrate. Beyond-use date assignment follows USP <795> categories: aqueous oral suspensions without preservative stabilization are assigned a 14-day beyond-use date under refrigeration at 2°C–8°C, while preservative-containing formulations may be assigned up to 35 days with documented stability-indicating assay. Batch size in veterinary compounding pharmacies rarely exceeds 500 g due to the low unit doses required for cats and small-breed dogs, and analytical confirmation of dose uniformity in capsule preparations is performed by weight variation per USP <2091> rather than individual content assay. Finished dosage types include hard gelatin capsules in size 3 or 4, flavored oral suspensions in amber PET dispensing bottles, and unit-dose oral syringes for hospitalized patients. Premix incorporation into bulk feed or water medicated concentrates is not a recognized dosage route for physostigmine in U.S., European Union, or Japanese veterinary regulatory frameworks, because the molecule is not approved for administration via feed or drinking water and published data for this specific configuration is limited; the narrow therapeutic index and susceptibility to hydrolytic degradation in alkaline feed matrices render this route pharmacokinetically impractical outside of controlled intravenous or topical protocols. Any manufacturer considering granulated physostigmine premix for rumen motility stimulation should be advised that therapeutic efficacy data in peer-reviewed literature is absent, and the absence of Maximum Residue Limit data in food-producing species would trigger regulatory non-compliance under EU Regulation 470/2009 and VICH GL49 residue guidelines.